Biostem Technologies (BSEM) Stock Price, News & Analysis

Company Overview

BioStem Technologies, Inc. is a biotechnology company focused on regenerative medicine and human tissue allograft products. Through its operating businesses, the company develops, processes, manufactures and distributes biologic products derived primarily from donated human birth tissue for use in wound care and other medical applications.

Its product portfolio includes placental-tissue-based allografts marketed under brands such as BioREtain and AmnioWrap. These products are designed to support the body’s natural healing processes and may be used by healthcare providers in wound-care, surgical, orthopedic and podiatric settings. The company also provides related processing and tissue-management capabilities through its BioStem Life Sciences operations.

BioStem Technologies serves the medical-provider and healthcare distribution markets, primarily in the United States, through direct and independent sales channels. The company’s business is centered on expanding the clinical and commercial use of regenerative biologics while maintaining tissue-processing and product-manufacturing operations.

Key Stats

• Today's Range: $2.13 to $2.49
• 50-Day Range: $2.39 to $4.74
• 52-Week Range: $2.13 to $8.40
• Volume: 99,199 shs
• Average Volume: 96,589 shs
• Market Capitalization: $42.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

Biostem Technologies Stock Analysis - MarketRank™

Biostem Technologies scored higher than 66% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Biostem Technologies has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Biostem Technologies has a consensus price target of $9.00, representing about 302.7% upside from its current price of $2.24.

Amount of Analyst Coverage

Biostem Technologies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.7 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biostem Technologies are expected to grow in the coming year, from ($1.90) to ($1.04) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biostem Technologies is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.53% of the float of Biostem Technologies has been sold short.

Short Interest Ratio / Days to Cover

Biostem Technologies has a short interest ratio ("days to cover") of 0.44, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biostem Technologies has recently decreased by 26.48%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biostem Technologies does not currently pay a dividend.

Dividend Growth

Biostem Technologies does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.36

News Sentiment

Biostem Technologies has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Biostem Technologies this week, compared to 2 articles on an average week.

Search Interest

Only 34 people have searched for BSEM on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biostem Technologies insiders have not sold or bought any company stock.

Percentage Held by Institutions

Biostem Technologies has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/13/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BSEM
• Previous Symbol: OTCMKTS:BSEM
• CIK: 1658678
• Web: N/A
• Phone: (954) 380-8342
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Biostem Technologies: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +296.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.58 million
• Net Margins: -76.02%
• Pretax Margin: N/A
• Return on Equity: -60.22%
• Return on Assets: -34.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.98
• Quick Ratio: 0.76

Sales & Book Value

• Annual Sales: $47.48 million
• Price / Sales: 0.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 18,670,000
• Free Float: N/A
• Market Cap: $42.36 million
• Optionable: N/A
• Beta: 0.17